Kynam Capital Management, LP Fate Therapeutics Inc Transaction History

Kynam Capital Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $182,653 - $435,472	-10,273 Reduced 11.25%	81,064 $2.01 Million
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $125,326 - $254,622	-4,224 Reduced 4.42%	91,337 $3.54 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $4.57 Million - $6.15 Million	95,561 New	95,561 $5.59 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.